Modality
Vaccine
MOA
HER2
Target
BET
Pathway
Innate Imm
T2DMM
Development Pipeline
Preclinical
~Oct 2019
→ ~Jan 2021
Phase 1
Apr 2021
→ Sep 2029
Phase 1Current
NCT06366258
2,850 pts·T2D
2021-04→2029-09·Not yet recruiting
2,850 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-143.5y awayPh2 Data· T2D
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Not yet…
Catalysts
Ph2 Data
2029-09-14 · 3.5y away
T2D
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06366258 | Phase 1/2 | T2D | Not yet recr... | 2850 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET |